Drugs / NEOTETRAZOLIUM
NEOTETRAZOLIUM
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05798533 | Jan → Sep 2023 | cancer | BGI, China | Unknown | No outcome recorded |
| Phase 1 | NCT05798546 | Sep 2022 → Sep 2023 | cancer | BGI, China | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEOTETRAZOLIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183691 ↗ |
| Known as | Neo-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05798546 ↗ |
| Known as | Neotetrazolium blue | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183691 ↗ |
| Known as | NEOTETRAZOLIUM CHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183691 ↗ |
| Known as | NSC-27621 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183691 ↗ |
| Modality | Cell therapy | “Neoantigen Targeting T Cells Suspension for Intravenous Infusion” NCT05798533 ↗ |
| Route | Intravenous | “Neo-T iv on day 0” NCT05798533 ↗ |